MA38302A1 - Anti-pdgfr-beta antibodies and their uses - Google Patents
Anti-pdgfr-beta antibodies and their usesInfo
- Publication number
- MA38302A1 MA38302A1 MA38302A MA38302A MA38302A1 MA 38302 A1 MA38302 A1 MA 38302A1 MA 38302 A MA38302 A MA 38302A MA 38302 A MA38302 A MA 38302A MA 38302 A1 MA38302 A1 MA 38302A1
- Authority
- MA
- Morocco
- Prior art keywords
- pdgfr
- beta
- antibodies
- diseases
- bind
- Prior art date
Links
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 abstract 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des anticorps qui se lient au récepteur bêta du facteur de croissance issu des plaquettes (pdgfr-bêta) et des procédés de leur utilisation. Selon certains modes de réalisation de l'invention, les anticorps sont des anticorps complètement humains qui se lient à pdgfr-bêta humain avec une affinité élevée. Les anticorps de l'invention sont utiles pour le traitement de maladies et de troubles associés à la signalisation par pdgfr-bêta et/ou l'expression cellulaire de pdgfr-bêta, tels que des maladies oculaires, des maladies fibrotiques, des maladies vasculaires et le cancer.The present invention relates to antibodies that bind to platelet-derived growth factor beta receptor (pdgfr-beta) and methods of their use. In some embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with pdgfr-beta signaling and / or cellular expression of pdgfr-beta, such as ocular diseases, fibrotic diseases, vascular diseases and the like. the cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750437P | 2013-01-09 | 2013-01-09 | |
| PCT/US2014/010395 WO2014109999A1 (en) | 2013-01-09 | 2014-01-07 | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38302A1 true MA38302A1 (en) | 2018-02-28 |
| MA38302B1 MA38302B1 (en) | 2018-10-31 |
Family
ID=56117360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38302A MA38302B1 (en) | 2013-01-09 | 2014-01-07 | Anti-pdgfr-beta antibodies and their uses |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR094379A1 (en) |
| MA (1) | MA38302B1 (en) |
-
2014
- 2014-01-07 MA MA38302A patent/MA38302B1/en unknown
- 2014-01-07 AR ARP140100052A patent/AR094379A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA38302B1 (en) | 2018-10-31 |
| AR094379A1 (en) | 2015-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY202018A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| MA42622B1 (en) | LIAISONS IN TIGIT AND THEIR USES | |
| MA45125B1 (en) | Anti-alpha-synuclein antibodies and their uses | |
| MA39061A1 (en) | Aplnr modulators and their uses | |
| MA44659B1 (en) | ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS | |
| TN2019000099A1 (en) | ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS | |
| MA39313B1 (en) | Anti-egfrviii antibodies and their uses in the treatment of various cancers | |
| MA46619B1 (en) | Anti-il-33 antibodies and their uses | |
| ZA202201874B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| MA47313A (en) | SUBCUTANEOUS FORMULATIONS OF HER2 ANTIBODIES | |
| MA44312A (en) | ANTIBODIES AND THEIR METHODS OF USE | |
| MA40041A (en) | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE | |
| MY169165A (en) | Anti-pdgfr-beta antibodies and uses thereof | |
| MA33534B1 (en) | Human antibodies have a high affinity against human 2 angiobots | |
| UA104663C2 (en) | CD127-BINDING ANTIBODY $CD127-BINDING ANTIBODY | |
| MA37945A1 (en) | Human antibodies to gfr3 and methods of use thereof | |
| MA38961A1 (en) | 3-phenyl-1h-pyrazolo [3,4-d] pyrimidin-4-ylamine compounds substituted for the crude tyrosine kinase inhibitors used to treat, for example, autoimmune, respiratory and inflammatory diseases, cancer, mastocytosis and osteoporosis | |
| MY187975A (en) | Antigen-binding proteins that activate the leptin receptor | |
| MA67288A1 (en) | Tubularysins and Tubularysin-Protein Conjugates | |
| PL1830881T3 (en) | Combining therapies targeting multiple toll-like receptors and use thereof | |
| JOP20220357A1 (en) | Binding of multispecific antibodies with BCMA | |
| MA39342B2 (en) | Il -21 antibody | |
| JOP20220204B1 (en) | human CD19 antibodies | |
| WO2019032945A9 (en) | Cd40-binding agents and uses thereof | |
| JOP20230109A1 (en) | Heavy chain antibodies bind to the alpha-folate receptor |